Page 1 of 304
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 2 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 3 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 4 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 5 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 6 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 7 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 8 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 9 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 10 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 11 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 12 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 13 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 14 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 15 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 16 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 17 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 18 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 19 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 20 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 21 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 22 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 23 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 24 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 25 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 26 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 27 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 28 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 29 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 30 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 31 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 32 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 33 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 34 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 35 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 36 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 37 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 38 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 39 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 40 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 41 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 42 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 43 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 44 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 45 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 46 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 47 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 48 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 49 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 50 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 51 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 52 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 53 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 54 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 55 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 56 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 57 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 58 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 59 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 60 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 61 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 62 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 63 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 64 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 65 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 66 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 67 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 68 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 69 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 70 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 71 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 72 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 73 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 74 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 75 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 76 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 77 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 78 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 79 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 80 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 81 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 82 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 83 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 84 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 85 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 86 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 87 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 88 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 89 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 90 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 91 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 92 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 93 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 94 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 95 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 96 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 97 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 98 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 99 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 100 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 101 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 102 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 103 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 104 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 105 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 106 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 107 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 108 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 109 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 110 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 111 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 112 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 113 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 114 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 115 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 116 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 117 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 118 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 119 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 120 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 121 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 122 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 123 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 124 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 125 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 126 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 127 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 128 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 129 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 130 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 131 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 132 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 133 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 134 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 135 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 136 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 137 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 138 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 139 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 140 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 141 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 142 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 143 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 144 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 145 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 146 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 147 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 148 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 149 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 150 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 151 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 152 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 153 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 154 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 155 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 156 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 157 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 158 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 159 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 160 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 161 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 162 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 163 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 164 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 165 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 166 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 167 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 168 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 169 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 170 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 171 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 172 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 173 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 174 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 175 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 176 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 177 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 178 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 179 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 180 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 181 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Wistar (Han) rats and Rhesus monkeys (each up to 2 weeks). In all studies, toxicokinetic 
analyses showed substantial systemic exposure to Ofev and, when measured, to its main 
metabolites BIBF 1202 and BIBF 1202 glucuronide. The changes observed during repeat-
dose studies of oral Ofev were either directly (e.g. thickened epiphyseal growth plates) or 
indirectly related (e.g. changes of red blood cell parameters) to the pharmacological activity 
of Ofev.
Adverse effects observed in Cynomolgus and Rhesus monkeys were diarrhoea, vomiting, 
increased salivation, and reduced body weight. Yellow discolouration of the skin was 
observed at the high dosage of 80 mg/kg (given up to 10 days) in the escalating dose study in 
Cynomolgus monkeys [n00230654-02]. In the 4-week toxicity study in Cynomolgus 
monkeys, no discolouration was observed at 60 mg/kg, and in the 13-week study no 
discolouration was noted at 30 mg/kg. No other observation of yellow discoloration of the 
skin or alterations of skin colour such as hypopigmentation or leucoplakia has been reported 
in mice, rats, rabbits and Rhesus monkeys. In none of the non-clinical single or repeat-dose 
toxicity studies with proven significant systemic exposure in mice (up to 2 years), rats (up to 
2 years), rabbits (Segment II, 13 days), dogs (up to 2 weeks), mini-pigs (up to 7 days), 
Cynomolgus (up to 13 weeks), and Rhesus monkeys (up to 52 weeks), there was any 
consistent evidence of drug-related discoloration of the skin.
Severe gastrointestinal effects were observed in dogs and mini-pigs, leading to high 
mortality. Observed effects included liquid faeces, vomiting, salivation, and 
paralysis/abnormal motor activity. The intestinal mucosa showed erosions, villous atrophy, 
and basophilia of crypt epithelium with nuclear crowding and mitoses, i.e. evidence for 
primary damage to the epithelial cells of the intestine. The high mortality in Beagle dogs was 
apparently due to a dose-limiting sensitivity for gastrointestinal adverse effects such as 
diarrhoea and vomiting, to which Beagle dogs were substantially more sensitive than other 
species.
Haematological changes across the studies were generally minimal to mild changes in red 
blood cell parameters (red blood cell count, haematocrit, haemoglobin, MCH, MCV, and 
reticulocytes). Changes in white blood cell, lymphocyte, and platelet count were also 
observed. Blood chemistry investigations revealed mild increases in ALT, AST, ALKP, total 
bilirubin, gamma-glutamyltransferase, and aldolase. However, increases in enzyme activities 
were not very prominent, were also occasionally observed in control animals, and were often 
interpreted as incidental, not as unequivocally drug-related.
Histopathological changes related to treatment with Ofev included dentopathy of the incisors, 
thickening of the growth plate (due to increased number of layers of hypertrophic 
chondrocytes) and increased swelling of chondrocytes in the basal layers of the articular 
cartilage in femur and tibia. The principal pathological changes observed included the 
presence of growth plate thickening in the femur/tibia and sternum, cortex and trabecular 
bone thinning in the sternum, and adrenal zona fasciculata atrophy in both sexes. There was 
no increase in the severity of the zona fasciculata atrophy with dose. All treatment-related 
changes showed complete or partial reversibility within the timescale of the toxicity studies; 
all changes were recoverable in principle. Growth plate changes recovered quickly.
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 182 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 183 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 184 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 185 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 186 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 187 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 188 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 189 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 190 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 191 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 192 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 193 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 194 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 195 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 196 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 197 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 198 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 199 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 200 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 201 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 202 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 203 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 204 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 205 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 206 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 207 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 208 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 209 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 210 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 211 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 212 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 213 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 214 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 215 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 216 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 217 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 218 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 219 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 220 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 221 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 222 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 223 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 224 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 225 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 226 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 227 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 228 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
______________________________________________________________
___________________________________________________________________
Page 229 of 304
Nintedanib
s00020175-34
_________
460 cases were identified with the above search criteria, the majority being report from study 
(73.9%).
Most patients were male: 67.0% vs. 29.3% female. Frequency of the event increased with age 
(11.7% of events reported in patients being between 18 and 64: 11.7%, between 65 to 
74 years: 34.3%, between 75 to 84 years: 36.3%, older than 84 years: 6.1%)
The majority of cases was serious (97.2%). For most events, the outcome was not 
reported/unknown/missing (43.3%), recovered/resolved (23.0%), or not recovered/not 
resolved/ongoing (21.5%). 11.1% of the cases had events a fatal outcome.
The most commonly reported MedDRA PTs (2% of the cases) were PE (61.1%), pulmonary 
thrombosis (22.4%), and DVT (16.3%).
Conclusion
The available safety information does not suggest any change to the current characterisation 
of this safety concern. The EU-SmPC and the EU-RMP correctly reflect the current benefit-
risk profile and this safety concern; no updates are warranted at present.
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
______________________________________________________________
___________________________________________________________________
Page 230 of 304
Nintedanib
s00020175-34
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 231 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 232 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 233 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 234 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 235 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 236 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 237 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 238 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 239 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 240 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 241 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 242 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 243 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 244 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 245 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 246 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 247 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 248 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 249 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 250 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 251 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 252 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 253 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 254 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 255 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 256 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 257 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 258 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 259 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 260 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 261 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 262 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 263 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 264 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 265 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 266 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 267 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 268 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 269 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 270 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 271 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 272 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 273 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 274 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 275 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 276 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 277 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 278 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 279 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
 
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 280 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 281 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 282 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 283 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 284 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 285 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 286 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 287 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 288 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 289 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 290 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 291 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 292 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 293 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 294 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 295 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 296 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 297 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 298 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 299 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 300 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 301 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
______________________________
___________________________________________________________________
Page 302 of 304
Nintedanib
s00020175-34 
_________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
______________________________
___________________________________________________________________
Page 303 of 304
Nintedanib
s00020175-34 
_________________________________________
Boehringer Ingelheim
Risk Management Plan
Version 11.4
___________________________________________________________________
Page 304 of 304
Nintedanib
s00020175-34
_______________________________________________________________________
